This Elevance Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Wall Street analysts upgraded TIGO, MWH, CNX, TNDM and ELV, with mixed price-target changes.
Last updated: 2026-11-19 02:45:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Praxis Precision Medicines, Inc. (PRAX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $304.90, with a market capitalization of $8.67B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $160.11 to $392.70. This page covers its latest market performance, valuation, price trends and company information.
$8.67B | |
$304.36 | |
$314.22 | |
$299.00 | |
$305.06 | |
377.09K | |
472.60K | |
-- | |
$392.70 | |
$160.11 | |
-- | |
2026-09-30 |
Praxis Precision Medicines, Inc. (PRAX) last closed at $304.90 as of 2026-11-19 00:58:00, up 0.19% ($0.58) from the previous close of $305.06.
During the latest regular trading session, PRAX traded between $299.00 and $314.22, with a volume of 377.09K shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Praxis Precision Medicines, Inc. (PRAX) moved from $332.97 to $304.90, representing a decline of 8.43% ($28.07).
The stock traded between $279.14 and $351.64 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 692.22 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 62.3%
PRAX is currently trading at $304.90, placing it 62.3% of the way from its 52-week low of $160.11 to its 52-week high of $392.70. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10,998 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Praxis Precision Medicines, Inc. and PRAX stock.
Wall Street analysts upgraded TIGO, MWH, CNX, TNDM and ELV, with mixed price-target changes.
Analysts upgraded UNFI, ZBH, NUE, MDT and PRAX, raising price targets and ratings to Buy or Overweight.
Wells Fargo analyst Benjamin Burnett upgrades Praxis Precision Medicine (NASDAQ:PRAX) from Equal-Weight to Overweight and raises the price target from $343 to $509.
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $800 to $1050.
Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.
Eligible investors can buy real shares of Praxis Precision Medicines, Inc. (PRAX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to PRAX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between PRAX shares and USD.
PRAX Shares to USD
1.00 PRAX shares = 304.901 USD
Calculations are estimates based on the latest available price and are for reference only.